Skip to main content
SpringerLink
Log in

Plant-Based β-Secretase (BACE-1) Inhibitors: A Mechanistic Approach to Encounter Alzheimer’s Disorder

  • Chapter
  • First Online:
Evidence Based Validation of Traditional Medicines

Abstract

BACE-1 (β-secretase) has emerged as a promising drug to treat Alzheimer’s disease (AD). BACE-1, an aspartic protease, acts on amyloid precursor protein (APP) prompting the formation and deposition of amyloid-β peptide (Aβ). BACE-1 hindrance has direct ramifications in AD pathology without generally influencing viability. However, inhibition of BACE-1 specifically through in vivo models has introduced numerous issues to the researchers. Since its identification in 2000, inhibitors covering a wide range of auxiliary classes have been structured and created. Advancement in these fields brought about targeted drug therapy that may reduce deposition of Aβ plaque in the brain. Natural product derivatives have always been a potential source of drug discovery process, and they are considered to be safe and economical. Flavonoids are an abundance of naturally delivered BACE-1 inhibitors. Citrus bioflavonoids are distinguished as potential noncompetitive BACE-1 inhibitors. Further, xanthones displayed the hindrance of Aβ conglomeration and BACE-1 activity in vitro and in cells, notwithstanding their radical scavenging and metal chelation capacity. The manuscript has been focused to deliver a refreshed learning with array of phytoextracts and lead molecules with BACE-1 inhibitory potential.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
eBook
USD 169.00
Price excludes VAT (USA)
Softcover Book
USD 219.99
Price excludes VAT (USA)
Hardcover Book
USD 219.99
Price excludes VAT (USA)

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

References

  • Abdul BAA, Vidhyavathi R, Magesh J, Vijayakumar M, Muneeb MM, Faiz MMTM (2018) Synthesis and Development of BACE 1 Inhibitor for Alzheimer’s Diseases from Medicinal Plants. Annual Research & Review in Biology 28(3):1–18

    Article  Google Scholar 

  • Anderson RN (2002) Deaths: leading causes for 2000. Natl Vital Stat Rep 50(16):1–85

    PubMed  Google Scholar 

  • Ansari N, Fariba K (2013) Molecular mechanism aspect of ER stress in Alzheimer’s disease: current approaches and future strategies. Curr Drug Targets 14(1):114–122

    Article  CAS  PubMed  Google Scholar 

  • Armstrong RA (2009) The molecular biology of senile plaques and neurofibrillary tangles in Alzheimer’s disease. Folia Neuropathol 47:289–299

    CAS  PubMed  Google Scholar 

  • Atanu B (2018) Phytoextracts and their derivatives affecting neurotransmission relevant to Alzheimer’s disease: an ethno-medicinal perspective. In: Akula R, Roshchina VV (eds) Neurotransmitters in plants: new achievements and perspectives. Taylor & Francis, New York, NY, pp 357–386

    Google Scholar 

  • Azimi S, Zonouzi A, Firuzi O et al (2017) Discovery of imidazopyridines containing isoindoline-1,3-dione framework as a new class of BACE1 inhibitors: design, synthesis and SAR analysis. Eur J Med Chem 138:729–737. https://doi.org/10.1016/j.ejmech.2017.06.040

    Article  CAS  PubMed  Google Scholar 

  • Bachurin SO, Bovina EV, Ustyugov AA (2017) Drugs in clinical trials for Alzheimer’s disease: the major trends. Med Res Rev 37:1186–1225. https://doi.org/10.1002/med.21434

    Article  CAS  PubMed  Google Scholar 

  • Balunas MJ, Kinghorn AD (2005) Drug discovery from medicinal plants. Life Sci 78:431–441

    Article  CAS  PubMed  Google Scholar 

  • Barao S, Moechars D, Lichtenthaler SF et al (2016) BACE1 physiological functions may limit its use as therapeutic target for Alzheimer’s disease. Trends Neurosci 39(3):158–169. https://doi.org/10.1016/j.tins.2016.01.003

    Article  CAS  PubMed  Google Scholar 

  • Ben Halima S, Mishra S, Raja KMP et al (2016) Specific inhibition of β-secretase processing of the Alzheimer disease amyloid precursor protein. Cell Rep 14:2127–2141. https://doi.org/10.1016/j.celrep.2016.01.076

    Article  CAS  PubMed  Google Scholar 

  • Berrino F (2002) Western diet and Alzheimer’s disease. Epidemiol Prev 26(3):107–115

    PubMed  Google Scholar 

  • Brinton RD, Yamazaki RS (1998) Advances and challenges in the prevention and treatment of Alzeimer’s disease. Pharm Res 15:386–398

    Article  CAS  Google Scholar 

  • Carlsson CM (2008) Lessons learned from failed and discontinued clinical trials for the treatment of Alzheimer’s disease: future directions. J Alzheimers Dis 15:327–338

    Article  PubMed  Google Scholar 

  • Choi SH, Hur JM, Yang EJ et al (2008a) Beta-secretase (BACE 1) inhibitors from Perilla frutescens var. acuta. Arch Pharm Res 31:183–187

    Article  CAS  PubMed  Google Scholar 

  • Choi YH, Yon GH, Hong KS et al (2008b) In vitro BACE 1 inhibitory phenolic components from the seeds of Psoralea corylifolia. Planta Med 74:1405–1408

    Article  CAS  PubMed  Google Scholar 

  • Choi CW, Choi YH, Cha MR et al (2011) In vitro BACE 1 inhibitory activity of resveratrol oligomers from the seed extract of Paeonia lactiflora. Planta Med 77:374–376

    Article  CAS  PubMed  Google Scholar 

  • Coan KE, Maltby DA, Burlingame AL et al (2009) Promiscuous aggregate-based inhibitors promote enzyme unfolding. J Med Chem 52:2067–2075

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Commenges D, Scotet V, Renaud S et al (2000) Intake of flavonoids and risk of dementia. Eur J Epidemiol 16:357–363

    Article  CAS  PubMed  Google Scholar 

  • Crouch PJ, Harding SM, White AR et al (2008) Mechanisms of a beta mediated neurodegeneration in Alzheimer’s disease. Int J Biochem Cell Biol 40:181–198

    Article  CAS  PubMed  Google Scholar 

  • Dai J, Sorribas A, Yoshida WY, Williams PG (2010) Sebestenoids A-D, BACE 1 inhibitors from Cordia sebestena. Phytochemistry 71:2168–2173

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dewachter I, Van LF (2002) Secretases as targets for the treatment of Alzheimer’s disease: the prospects. Lancet Neurol 1:409–416

    Article  CAS  PubMed  Google Scholar 

  • Eglen RM (2002) Enzyme fragment complementation: a flexible high throughput screening assay technology. Assay Drug Dev Technol 1:97–104

    Article  CAS  PubMed  Google Scholar 

  • Eric K, Bard DS (2016) The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem 139(2):237–252

    Google Scholar 

  • Feng BY, Shoichet BK (2006) A detergent-based assay for the detection of promiscuous inhibitors. Nat Protoc 1:550–553

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Fenical WH, Jensen PJ (2006) Developing a new resource for drug discovery: marine actinomycete bacteria. Nat Chem Biol 2:666–673

    Article  CAS  PubMed  Google Scholar 

  • Gunasekera SP, Miller MW, Kwan JC et al (2010) Molassamide, a dipeptide serine protease inhibitor from the marine cyanobacterium Dichothrix utahensis. J Nat Prod 73:459–462

    Article  CAS  PubMed  Google Scholar 

  • Guo T, Hobbs DW (2006) Development of BACE 1 inhibitors for Alzheimer’s disease. Curr Med Chem 13:1811–1829

    Article  CAS  PubMed  Google Scholar 

  • Gupta BM, Bala A (2013) Alzheimer’s disease research in India: a scientometric analysis of publications output during 2002-11. Res Neurol Int J 2013:1–11. https://doi.org/10.5171/2013.204542

    Article  Google Scholar 

  • Gurib-Fakim A (2006) Medicinal plants: traditions of yesterday and drugs of tomorrow. Mol Aspect Med 27:1–93

    Article  CAS  Google Scholar 

  • Hadden MK, Hill SA, Davenport J et al (2009) Synthesis and evaluation of Hsp90 inhibitors that contain the 1,4-naphthoquinone scaffold. Bioorg Med Chem 17:634–640

    Article  CAS  PubMed  Google Scholar 

  • Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356

    Article  CAS  PubMed  Google Scholar 

  • Huang Y, Mucke L (2012) Alzheimer mechanisms and therapeutic strategies. Cell 148(6):1204–1222

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hwang EM, Ryu YB, Kim HY et al (2008) BACE 1 inhibitory effects of lavandulyl flavanones from Sophora flavescens. Bioorg Med Chem 16:6669–6674

    Article  CAS  PubMed  Google Scholar 

  • Hyun SK, Sick WW, Sung LS et al (1997) Elgonica-dimers A and B, two potent alcohol metabolism inhibitory constituents of Aloe arborescens. J Nat Prod 60:1180–1182

    Article  Google Scholar 

  • Jeon YH, Heo YS, Kim CM et al (2005) Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development. Cell Mol Life Sci 62:1198–1220

    Article  CAS  PubMed  Google Scholar 

  • Jeon M, Huong N, Sami B, Kai Z (2008) Redundancy and compensation in axon guidance: genetic analysis of the Drosophila Ptp10D/Ptp4E receptor tyrosine phosphatase subfamily. Neural Dev 3(3):1–18

    Google Scholar 

  • Jeona SY, Kwona SH, Seong YH, Bae K, Hur JM, Lee YY, Suh DY, Song KS (2007) β-secretase (BACE1)-inhibiting stilbenoids from Smilax Rhizoma. Phytomedicine 14(6):403–408

    Article  Google Scholar 

  • Jeong SH, Ryu YB, Curtis-Long MJ et al (2009) Tyrosinase inhibitory polyphenols from roots of Morus ihou. J Agric Food Chem 57:1195–1203

    Article  CAS  PubMed  Google Scholar 

  • Jung HA, Jung YJ, Hyun HK et al (2010) Selective cholinesterase inhibitory activities of a new monoterpene diglycoside and other constituents from Nelumbo nucifera stamens. Biol Pharm Bull 33:267–272

    Article  CAS  PubMed  Google Scholar 

  • Kang HS, Kim HR, Byun DS et al (2004) Tyrosinase inhibitors isolated from the edible brown alga Ecklonia stolonifera. Arch Pharm Res 27:1226–1232

    Article  CAS  PubMed  Google Scholar 

  • Kinghorn AD (2001) Pharmacognosy in the 21st century. J Pharm Pharmacol 53:135–148

    Article  CAS  Google Scholar 

  • Ko PC, Higgins JA, Kilduff PT et al (2005) Evidence for intact selective attention in Alzheimer’s disease patients using a location priming task. Neuropsychology 19:381–389

    Article  PubMed  Google Scholar 

  • Lee HJ, Seong YH, Bae KH et al (2005) β-Secretase (BACE 1) inhibitors from Sanguisorbae radix. Arch Pharm Res 28:799–803

    Article  CAS  PubMed  Google Scholar 

  • Mahesh G, Tasneem S (2014) Biomarker controversies and diagnostic difficulties in Alzheimer’s disease. Am J Phytomed Clin Ther 2(4):463–468

    Google Scholar 

  • McArdle BM, Quinn RJ (2007) Identification of protein fold topology shared between different folds inhibited by natural products. Chem Bio Chem 8:788–798

    Article  CAS  PubMed  Google Scholar 

  • Mei Z, Situ B, Tan X et al (2010) Cryptotanshinione upregulates alpha-secretase by activation PI3K pathway in cortical neurons. Brain Res 12:165–173

    Article  Google Scholar 

  • Miguel AM, Emília S (2019) BACE-1 and γ-secretase as therapeutic targets for Alzheimer’s disease. Pharmaceuticals (Basel) 12(41):1–31

    Google Scholar 

  • Montenegro RC, Araujo AJ, Molina MT et al (2010) Cytotoxic activity of naphthoquinones with special emphasis on juglone and its 5-O-methyl derivative. Chem Biol Interact 184:439–448

    Article  CAS  PubMed  Google Scholar 

  • Muto N, Inouye K, Inaba A et al (1987) Inhibition of cytochrome P-450-linked monooxygenase systems by naphthoquinones. Biochem Biophys Res Commun 146:487–494

    Article  CAS  PubMed  Google Scholar 

  • Nam Y, Lee D (2013) Ameliorating effect of Zhizi (Fructus Gardeniae) extract and its glycosides on scopolamine-induced memory impairment. J Tradit Chin Med 15:223–227

    Article  Google Scholar 

  • Ono K, Yoshiike Y, Takashima A et al (2003) Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer’s disease. J Neurochem 7:172–181

    Article  Google Scholar 

  • Parihar MS, Hemnani T (2004) Alzheimer’s disease pathogenesis and therapeutic interventions. J Clin Neurosci 11(5):456–467

    Article  CAS  PubMed  Google Scholar 

  • Perry E, Walker M, Grace J, Perry R (1999) Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci 22(6):273–280

    Article  CAS  PubMed  Google Scholar 

  • Philomena G (2011) Concerns regarding the safety and toxicity of medicinal plants—an overview. J Appl Pharm Sci 1(6):40–44

    Google Scholar 

  • Roberds SL, Anderson J, Basi G et al (2001) BACE knockout mice are healthy despite lacking the primary beta-secretase activity in brain: implications for Alzheimer’s disease therapeutics. Hum Mol Genet 10:1317–1324

    Article  CAS  PubMed  Google Scholar 

  • Ross JA, Kasum CM (2002) Dietary flavonoids: bioavailability, metabolic effects, and safety. Annu Rev Nutr 22:19–34

    Article  CAS  PubMed  Google Scholar 

  • Salloway S, Mintzer J, Weiner MF et al (2008) Disease-modifying therapies in Alzheimer’s disease. Alzheimers Dement 4:65–79

    Article  CAS  PubMed  Google Scholar 

  • Scarpini E, Schelterns P, Feldman H (2003) Treatment of Alzheimer’s disease: current status and new perspectives. Lancet Neurol 2:539–547

    Article  CAS  PubMed  Google Scholar 

  • Selkoe DJ (2004) Alzheimer’s disease: mechanistic understanding predicts novel therapies. Ann Intern Med 140:627–638

    Article  CAS  PubMed  Google Scholar 

  • Shankar GM, Brenda LB, Matthew T, Dominic MW, Dennis JS, Bernardo LS (2007) Natural oligomers of the Alzheimer amyloid-beta protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J Neurosci 27(11):2866–2875

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shimmyo Y, Kihara T, Akaike A et al (2008) Multifunction of myricetin on Aβ: neuroprotection via a conformational change of Aβ and reduction of Aβ via the interference of secretases. J Neurosci Res 86:368–377

    Article  CAS  PubMed  Google Scholar 

  • Skovronsky DM, Lee VMY, Trojanowsky JQ (2006) Neurodegenerative diseases: new concepts of pathogenesis and their therapeutic implications. Annu Rev Pathol 1:151–170

    Article  CAS  PubMed  Google Scholar 

  • Speranza G, Data G, Lunazzi L et al (1986) A new Diglucosylated 6-Phenyl-2-pyrone from Kenya Aloe. J Nat Prod 45:800–805

    Article  Google Scholar 

  • Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer’ disease amyloid hypothesis: a genetic perspective. Cell 120:545–555

    Article  CAS  PubMed  Google Scholar 

  • Tariot PN, Farlow MR, Grossberg GT et al (2004) Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 291:317–324

    Article  CAS  PubMed  Google Scholar 

  • Tauraite D, Razumas V, Butkus E (2009) Lipophilic 1,4-naphthoquinone derivatives: synthesis and redox properties in solution and entrapped in the aqueous cubic liquid-crystalline phase of monoolein. Chem Phys Lipids 159:45–50

    Article  CAS  PubMed  Google Scholar 

  • Vaidya AB (1997) The status and scope of Indian medicinal plants acting on the central nervous system. Indian J Pharmacol 29:S340:228–34

    Google Scholar 

  • Vassar R (2004) BACE1: the beta-secretase enzyme in Alzheimer’s disease. J Mol Neurosci 23(1–2):105–114

    Article  CAS  PubMed  Google Scholar 

  • Vladimir V, Sophia R (2018) Results of beta secretase-inhibitor clinical trials support amyloid precursor protein-independent generation of beta amyloid in sporadic Alzheimer’s disease. Med Sci (Basel) 6(2):45–58

    Google Scholar 

  • Youdim KA, Qaiser MZ, Begley DJ et al (2004) Flavonoid permeability across an in situ model of the blood-brain barrier. Free Radical Bio Med 36:592–604

    Article  CAS  Google Scholar 

  • Yu PN, Terry CTO, Nancy YIP (2015) Plant alkaloids as drug leads for Alzheimer’s disease. Neurochem Int 32(4):1e–11e

    Google Scholar 

  • Zhang F, Jiang L (2015) Neuroinflammation in Alzheimer’s disease. Neuropsychiatr Dis Treat 11:243–256

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgments

The authors express gratitude to Assam Down Town University and NEF College of Pharmacy, Assam, for support.

Author information

Authors and Affiliations

  1. Faculty of Pharmaceutical Science, Assam Down Town University, Guwahati, Assam, India

    Atanu Bhattacharjee & Saikat Sen

  2. NEF College of Pharmacy, Guwhati, Assam, India

    Raja Chakraborty

Authors
  1. Atanu Bhattacharjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raja Chakraborty
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Saikat Sen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Atanu Bhattacharjee .

Editor information

Editors and Affiliations

  1. Pharmaceutical Technology, Jadavpur University, Kolkata, West Bengal, India

    Subhash C. Mandal

  2. NEF College of Pharmacy, Guwahati, Assam, India

    Raja Chakraborty

  3. Faculty of Pharmaceutical Science, Assam down town University, Guwahati, Assam, India

    Saikat Sen

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Bhattacharjee, A., Chakraborty, R., Sen, S. (2021). Plant-Based β-Secretase (BACE-1) Inhibitors: A Mechanistic Approach to Encounter Alzheimer’s Disorder. In: Mandal, S.C., Chakraborty, R., Sen, S. (eds) Evidence Based Validation of Traditional Medicines. Springer, Singapore. https://doi.org/10.1007/978-981-15-8127-4_8

Download citation

Publish with us

Policies and ethics

Search

Navigation